For 31 hormone receptor (HR)+/HER2− breast cancers, there were two clusters: One with the co-occurrence of ATM, FGFR1, and WT1 frameshift mutations, and the other with JAK3 splice site and FGFR2 frameshift mutations (Figure 3). Here, FGFR2 is linked to breast carcinoma.